コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 gery, chemotherapy, radiotherapy, or no anti-cancer therapy).
2 ogression, and also pose major obstacles for cancer therapy.
3 mplications for development of resistance to cancer therapy.
4 otential of this interaction as a target for cancer therapy.
5 is the only class of antibodies employed for cancer therapy.
6 iferation, demonstrating a novel approach in cancer therapy.
7 eptor, frizzled (FZD), may have potential in cancer therapy.
8 xploration of the benefits of fasting/FMD in cancer therapy.
9 fying enzymes, provides novel strategies for cancer therapy.
10 RPC may reveal potential vulnerabilities for cancer therapy.
11 ve been regarded as a common denominator for cancer therapy.
12 r patients that occur prior to initiation of cancer therapy.
13 nctions as an alternative model for curative cancer therapy.
14 targeting telomerase with modified dNTPs in cancer therapy.
15 ficacy is a promising strategy for effective cancer therapy.
16 RNA (RG4s) offers an interesting approach to cancer therapy.
17 ibitors of many cancers and hold promise for cancer therapy.
18 eyond 120 days, and/or initiation of another cancer therapy.
19 7RB can be a potential target for pancreatic cancer therapy.
20 ore might be a good candidate for epigenetic cancer therapy.
21 implementation of personalized combinatorial cancer therapy.
22 hotothermal efficacies can be maintained for cancer therapy.
23 l-1) has emerged as an attractive target for cancer therapy.
24 ld have widespread benefits for the field of cancer therapy.
25 s of allosteric inhibitors opens avenues for cancer therapy.
26 ery are summarized with the special focus on cancer therapy.
27 inum complexes beyond those in catalysis and cancer therapy.
28 ials in PET-guided, CDT-enhanced combination cancer therapy.
29 class of transcript attractive for targeted cancer therapy.
30 of LSD1 have potential to be beneficial as a cancer therapy.
31 in human cancers and may be ideal targets of cancer therapy.
32 ranscription factor with great potential for cancer therapy.
33 g CHK1 and B-family polymerase inhibitors in cancer therapy.
34 echanisms that may influence the response to cancer therapy.
35 has shown promise as a molecularly targeted cancer therapy.
36 rogression, have become rational targets for cancer therapy.
37 nthesis, and is a well-recognized target for cancer therapy.
38 microenvironment is an attractive avenue for cancer therapy.
39 and molecules to program CAF composition for cancer therapy.
40 ngs have implications for PRC2 inhibition in cancer therapy.
41 that targeting citrin may be of benefit for cancer therapy.
42 tential to improve the efficacy of DSF-based cancer therapy.
43 BAQ ONNs have enormous potential to improve cancer therapy.
44 etastases may permit an adjuvant approach to cancer therapy.
45 r initiation, maintenance, and resistance to cancer therapy.
46 cle delivered short PNA probes for potential cancer therapy.
47 candidate targeting mitochondria function in cancer therapy.
48 es genome stability and has implications for cancer therapy.
49 his enzyme is targeted by PARP inhibitors in cancer therapy.
50 iagnostics and bioengineering strategies for cancer therapy.
51 and we review their potential as targets for cancer therapy.
52 ccessful application of molecularly targeted cancer therapy.
53 as a promising biomarker for efficient WEE1 cancer therapy.
54 nsiderable interest as potential targets for cancer therapy.
55 cer, anemia remains a common complication of cancer therapy.
56 cell surface receptors are a new modality of cancer therapy.
57 evelopment of early detection of response to cancer therapy.
58 susceptibility and promising drug target for cancer therapy.
59 ome complex may be an effective approach for cancer therapy.
60 e targeting in glioblastoma multiforme (GBM) cancer therapy.
61 purposes of regenerative medicine as well as cancer therapy.
62 different delivery strategies for DSF-based cancer therapy.
63 potential of targeting m(6)A regulators for cancer therapy.
64 inical potential of autophagy inhibition for cancer therapy.
65 e development and use of genotoxic agents in cancer therapy.
66 ng the BD2 domain of BET family proteins for cancer therapy.
67 ithin tumors is a major barrier to effective cancer therapy.
68 nanoparticles under AMF, as a new avenue for cancer therapy.
69 solubilize and load paclitaxel for targeted cancer therapy.
70 s is crucial for the success of personalized cancer therapy.
71 rodrug currently in clinical development for cancer therapy.
72 apy, has emerged as an attractive target for cancer therapy.
73 e challenges to bringing PDT into mainstream cancer therapy.
74 adually emerged as the preferred approach to cancer therapy.
75 and may thus serve as a potential target for cancer therapy.
76 red when targeting one-carbon metabolism for cancer therapy.
77 d therapeutic agents has opened a new era in cancer therapy.
78 on, and/or diet now offer new approaches for cancer therapy.
79 binations and immunotherapy combinations for cancer therapy.
80 aging, represses cancer growth and improves cancer therapy.
81 mit immune responses and present barriers to cancer therapy.
82 nd approaches exploiting the MMEJ pathway in cancer therapy.
83 g Aurora kinases have attracted attention in cancer therapy.
84 examine its potential application in MFH for cancer therapy.
85 tumor immune response, with implications for cancer therapy.
86 bility and enables targeted drug delivery in cancer therapy.
87 sents a candidate antigen for antibody-based cancer therapy.
88 DNA nanostructures have shown potential in cancer therapy.
89 hts the broad potential of targeting FTO for cancer therapy.
90 metabolism as well as promising targets for cancer therapy.
91 en recognized as a promising new approach in cancer therapy.
92 eradication and is a promising approach for cancer therapy.
93 ell lung cancer is a persistent challenge in cancer therapy.
94 otential new drug for triple-negative breast cancer therapy.
95 ast few years represents a paradigm shift in cancer therapy.
96 on is the mainstay of radiation treatment in cancer therapy.
97 argeted drug-delivery systems (Nano-TDDS) in cancer therapy.
98 checkpoint blockade (ICB) has revolutionized cancer therapy.
99 ls, have been well studied in the context of cancer therapy.
100 so mTOR has become an attractive target for cancer therapy.
101 ng an effective approach for highly targeted cancer therapy.
102 and offer a novel approach to drug-resistant cancer therapy.
103 been explored as an antiangiogenic target in cancer therapy.
104 g Gd-based nanotheranostics for image-guided cancer therapy.
105 death ultimately renders them hot targets in cancer therapy.
106 future efforts to exploit this knowledge for cancer therapy.
107 d is re-emerging as an attractive target for cancer therapy.
108 process for the mutation-oriented RAF-kinase cancer therapy.
109 , MDS treatment history, or history of prior cancer therapy.
110 receptor represents an attractive target for cancer therapy.
111 anomedicine represents an important class of cancer therapy.
112 shedding light on cellular responses to anti-cancer therapies.
113 gic and oncogenic roles of EGFR and targeted cancer therapies.
114 mechanism to acquire resistance to standard cancer therapies.
115 xplored to increase the efficacy of existing cancer therapies.
116 investigated as a means to develop targeted cancer therapies.
117 s considered a promising approach to support cancer therapies.
118 ex, comorbidities, health care use, and past cancer therapies.
119 KTR-214 synergizes with T cell-mediated anti-cancer therapies.
120 ular design of the intended ADCs as targeted cancer therapies.
121 fective T cell immunity and its relevance in cancer therapies.
122 epitopes, making them attractive targets for cancer therapies.
123 ommunities developing the next generation of cancer therapies.
124 in patient biopsies to inform the design of cancer therapies.
125 velopment of potent, clinically translatable cancer therapies.
126 ay be a viable target for development of new cancer therapies.
127 s it possible to envision new MUTYH-specific cancer therapies.
128 nteractions may potentially be exploited for cancer therapies.
129 m and pulmonary hypertension associated with cancer therapies.
130 chanism of action, and potential in targeted cancer therapies.
131 tumor and in distant organs before and after cancer therapies.
132 ave varied responses to anticancer drugs and cancer therapies.
133 d often untapped accomplice of many standard cancer therapies.
134 ity of tumours to optimise and engineer anti-cancer therapies.
135 munity is pivotal for improving immune-based cancer therapies.
136 ant cell states remain a barrier to targeted cancer therapies.
137 repair pathways simultaneously as effective cancer therapies.
138 tions for widely applicable yet personalized cancer therapies.
139 levant in vivo model systems for identifying cancer therapies.
140 and enhance the efficacy of a wide range of cancer therapies.
141 and DNA modifications are targets of current cancer therapies.
142 itate optimal patient selection for targeted cancer therapies.
143 ies, making it an attractive target of novel cancer therapies.
144 tibody-drug conjugates as potential targeted cancer therapies.
145 f stemness in the quest to develop effective cancer therapies.
146 odalities for vascular toxicities related to cancer therapies.
147 he importance of platinum [Pt(II)] agents in cancer therapy, accumulating reports showed the treatmen
151 d severe adverse events associated with anti-cancer therapies and can be a source of drug attrition.
152 ses cancer cells to nucleoside-analogue anti-cancer therapies and is linked with DNA repair and suppr
153 toward antibody-drug conjugates for targeted cancer therapies and provide inspiration for further adv
154 ome recent research on targeted delivery for cancer therapy and also discusses examples of types of e
156 unteracting PARP inhibitor resistance during cancer therapy and repurposing PARP inhibitors for the t
157 o date in the rapidly evolving world of lung cancer therapy and serve as key members of multidiscipli
158 iomarker of patient outcome to perioperative cancer therapy and surgical resection in patients with g
159 merase will have a transformative impact for cancer therapy and the prospect of clinically effective
160 on desorption, Coulombic decay, photodynamic cancer therapies, and may yield important insights into
161 rients in the diet can alter the efficacy of cancer therapies, and some of the newest developments in
162 ould be extended to other nanoparticle-based cancer therapies, and support the development of persona
163 ue and are different to those of traditional cancer therapies, and typically have a delayed onset and
164 us injection and pulmonary delivery for lung cancer therapy, and (iii) computational simulations that
166 apoptosis is often necessary for successful cancer therapy, and the non-invasive monitoring of apopt
168 rential survival of patients undergoing anti-cancer therapies are of great interest because they can
169 and prevention of vascular toxic effects of cancer therapies are outlined in the context of availabl
172 that continue to refine our understanding of cancer, therapies are now being developed to treat cance
173 ontribution of these changes to responses to cancer therapy as ageing predicts outcomes of therapy, i
175 are in consideration to make advancement in cancer therapy as the new developed methods exhibited an
176 influence the efficacy and toxic effects of cancer therapies, as well as quality of life following c
177 is a promising form of gene interaction for cancer therapy, as it is able to identify specific genes
178 CE Oncolytic viruses are being developed for cancer therapy, as they selectively target, infect, and
180 sults caution against the "Achilles heel" in cancer therapies based on primary tumor characterization
182 Rexinoids are promising drug candidates for cancer therapy because of their ability to modulate gene
183 e between groups in Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) score r
185 on is not only a common clinical approach in cancer therapy but also an experimental injury model use
186 geted radionuclides have great potential for cancer therapy but are sometimes associated with insuffi
187 Antiangiogenesis is a promising approach to cancer therapy but is limited by the lack of tumor-homin
188 gineered) T cells is a promising approach in cancer therapy but needs improvement for more effective
189 ed not only to peptide activators of p53 for cancer therapy, but also to peptide therapeutics in gene
190 ntibodies has revolutionized many aspects of cancer therapy, but the efficacy of these breakthrough t
191 gineered cytokines are gaining importance in cancer therapy, but these products are often limited by
192 S can serve a wide range of users and assist cancer therapy by moving away from the 'one-size-fits-al
193 receptors that have demonstrated efficacy in cancer therapy by targeting immobilized antigens on the
197 r the 50 year old hypothesis that a curative cancer therapy can be constructed on the basis of indepe
198 ely review contemporary literature regarding cancer therapies, cancer stage specific prognosis, the k
199 lth Survey [SF-12], Functional Assessment of Cancer Therapy-Cervical [FACT-Cx], EuroQoL-5D [EQ-5D], a
200 n using the 37-item Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog) questionnai
202 to cancer resistance and pose challenges for cancer therapy due to differential genomic rearrangement
203 nd HIF-2 inhibitors have limited efficacy in cancer therapy due to the development of resistance.
204 tiangiogenic agents have limited efficacy in cancer therapy due to the development of resistance.
205 ) receptor (hY(1)R) are promising targets in cancer therapy due to their high overexpression on cance
206 COMET as a new target to improve drug-based cancer therapies, especially in BRAF-mutated and MET-add
207 DDS may find applications in high effective cancer therapy, especially for tumors with high trypsin
212 tracellular redox status can be a target for cancer therapy, FGF/FGFR blockade by FGF trapping or tyr
213 e phase III (neo)adjuvant trials of prostate cancer therapies for primary radiation therapy-based tri
215 r awareness of the vascular toxic effects of cancer therapies has further unveiled the urgent needs i
219 Subsequently, the field of NK cell-based cancer therapy has grown exponentially and currently con
220 ecade, the growing interest in targeted lung cancer therapy has guided researchers toward the cutting
222 use of magnetic fluid hyperthermia (MFH) for cancer therapy has shown promise but lacks suitable meth
226 on in scores on the Functional Assessment of Cancer Therapy Hepatobiliary Symptom Index 8 (FHSI-8), a
227 ic activity has been extensively studied for cancer therapy; however, the mechanisms underlying DOT1L
228 Cs) become enriched in humans following anti-cancer therapy implicates CSCs as key contributors to tu
230 rs (ICIs), which have proven to be effective cancer therapies in many malignancies, has spawned great
233 have been developed to induce pyroptosis for cancer therapy, including ions, small-molecule drugs and
234 biomarker discovery should be considered as cancer therapy increasingly heads towards a personalized
240 ietary changes could improve the response to cancer therapy is extremely attractive to many patients,
244 mor hypoxia, the "Achilles' heel" of current cancer therapies, is indispensable to drug resistance an
246 ) metrics using the Functional Assessment of Cancer Therapy Kidney Symptom Index-19 and the Brief Fat
249 hifts in oral microbiota caused by cytotoxic cancer therapies may also contribute to the progression
251 striction remains an attractive strategy for cancer therapy, metabolic adaptations limit its effectiv
258 es (ADCs) are now clinically established for cancer therapy, peptide-drug conjugates (PDCs) are gaini
259 NPs) with desirable performance for combined cancer therapy, photothermal and radiation therapy (RT),
260 assessed using the Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire and the E
261 gical endpoint of relevance to the fields of cancer therapy (radiotherapy), public health (biodosimet
266 st that the 'precision medicine' paradigm of cancer therapy requires treatment to be personalized to
268 e highlight the role of the Hippo pathway in cancer therapy resistance and tumor immunogenicity.
270 of oncogenes(1-3), and to the development of cancer therapy resistance by increasing the expression o
272 nts, as it reduces the viability of prostate cancer-therapy-resistant cells in both CSCs and non-CSC
273 ovides invaluable information for evaluating cancer therapy response and screening preclinical antica
274 with a number of other targets important in cancer therapy, review the present status, and discuss f
275 is phosphorylation as a potential target for cancer therapy.See related commentary by Horikawa, p.
276 ed late mortality (including late effects of cancer therapy), subsequent malignant neoplasms (SMNs),
277 e cardiotoxicity associated with traditional cancer therapies, such as anthracycline, trastuzumab or
280 rnal causes, but include the late effects of cancer therapy) than did childhood cancer survivors (SMR
281 licated in survivors who had been exposed to cancer therapies that are associated with phenotype risk
283 Drug resistance has been a major threat in cancer therapies that necessitates the development of ne
284 frameworks to evaluate the clinical value of cancer therapies: the ASCO-Value Framework (ASCO-VF) and
285 f autophagy in established tumors and during cancer therapy; this has led to the launch of dozens of
286 stance to multiple conventional and targeted cancer therapies through diverse mechanisms including ma
287 ntity nanomedicine (ONN) strategy to improve cancer therapy through incorporation of the self-assembl
288 affordable strategy to improve the reach of cancer therapy to low income regions with such new trick
290 and have been associated with resistance to cancer therapy, tumor relapse, malignancy, immunosuppres
292 from a cell-mortality perspective to various cancer therapies, we report a label-free and real time m
293 CD44 is regarded as an excellent target for cancer therapy when this interaction can be blocked.
294 rological disorders but is also exploited in cancer therapy where TOP1ccs are the target of widely us
295 been recognized as a promising strategy for cancer therapy, which may expand the clinical utility of
297 riched in current or former smokers, whereas cancer therapy with radiation, platinum and topoisomeras
300 dies has shown to be a promising strategy in cancer therapy, yet clinical response in many types of c